The clinical relevance of Mycobacterial pharmacogenetics
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pillay, 2007, Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa, Clin Infect Dis, 45, 1409, 10.1086/522987
WHO
van Rie, 1999, Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling “strain W” among noninstitutionalized, human immunodeficiency virus-seronegative patients, J Infect Dis, 180, 1608, 10.1086/315054
Victor, 2007, Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the western Cape of South Africa, Int J Tuberc Lung Dis, 11, 195
Johnson, 2008, Drug susceptibility testing using molecular techniques can enhance tuberculosis diagnosis, J Infect Dev Countries, 2, 40
van Helden, 2006, Antimicrobial resistance in tuberculosis: an international perspective, Expert Rev Anti Infect Ther, 4, 759, 10.1586/14787210.4.5.759
National Committee for Clinical Laboratory Standards, 2003
Sirgel, 2008, Measuring inhibitory concentrations in Mycobacteria
Victor, 1997, Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis, J Med Microbiol, 46, 847, 10.1099/00222615-46-10-847
Kim, 2003, Molecular analysis of isoniazid resistance in Mycobacterium tuberculosis isolates recovered from South Korea, Diagn Microbiol Infect Dis, 47, 497, 10.1016/S0732-8893(03)00132-9
Ramaswamy, 2003, Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis, Antimicrob Agents Chemother, 47, 1241, 10.1128/AAC.47.4.1241-1250.2003
Abe, 2008, Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan, J Clin Microbiol, 46, 2263, 10.1128/JCM.00561-08
Lacoma, 2008, GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples, J Clin Microbiol, 46, 3660, 10.1128/JCM.00618-08
Becton, Dickinson and Company
Schaaf, 2007, Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children, Eur J Clin Microbiol Infect Dis, 26, 203, 10.1007/s10096-007-0257-9
Katiyar, 2008, A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis, Int J Tuberc Lung Dis, 12, 139
Yew, 2006, Antituberculosis drugs and hepatotoxicity, Respirology, 11, 699, 10.1111/j.1440-1843.2006.00941.x
Johnson, 2006, Drug resistance in Mycobacterium tuberculosis, Curr Issues Mol Biol, 8, 97
Mokrousov, 2002, High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001, Antimicrob Agents Chemother, 46, 1417, 10.1128/AAC.46.5.1417-1424.2002
Baker, 2005, Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC −46A polymorphism, Antimicrob Agents Chemother, 49, 1455, 10.1128/AAC.49.4.1455-1464.2005
Hillemann, 2007, Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens, J Clin Microbiol, 45, 2635, 10.1128/JCM.00521-07
Clemente, 2008, Phenotypic and genotypic characterization of drug-resistant Mycobacterium tuberculosis strains, Diagn Microbiol Infect Dis, 62, 199, 10.1016/j.diagmicrobio.2008.06.013
Gali, 2006, Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance, J Clin Microbiol, 44, 201, 10.1128/JCM.44.1.201-205.2006
Springer, 2008, Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping, J Clin Microbiol, 46, 4064, 10.1128/JCM.01114-08
Mitchison, 1973, Plasma concentration of isoniazid in the treatment of tuberculosis, 169
Dong, 2000, Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis, Antimicrob Agents Chemother, 44, 2581, 10.1128/AAC.44.9.2581-2584.2000
Mitchison, 2000, Role of individual drugs in the chemotherapy of tuberculosis, Int J Tuberc Lung Dis, 4, 796
Pai, 2006, New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance, Expert Rev Mol Diagn, 6, 423, 10.1586/14737159.6.3.423
Ling, 2008, GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis, Eur Respir J, 32, 1165, 10.1183/09031936.00061808
Barnard, 2008, Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa, Am J Respir Crit Care Med, 177, 787, 10.1164/rccm.200709-1436OC
Selkon, 1964, The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid and PAS, Bull World Health Organ, 31, 273
Kucers, 1997, Drugs mainly for tuberculosis, 1179
Parkin, 1997, Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis, Am J Respir Crit Care Med, 155, 1717, 10.1164/ajrccm.155.5.9154882
Mlambo, 2008, Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa, Int J Tuberc Lung Dis, 12, 99
Jindani, 2003, Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days, Am J Respir Crit Care Med, 167, 1348, 10.1164/rccm.200210-1125OC
Morlock, 2003, ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates, Antimicrob Agents Chemother, 47, 3799, 10.1128/AAC.47.12.3799-3805.2003
Baulard, 2000, Activation of the pro-drug ethionamide is regulated in mycobacteria, J Biol Chem, 275, 28326, 10.1074/jbc.M003744200